KODK vs AMGN vs GILD vs XRX vs ABBV

For growth investors, Xerox Holdings Corporation (XRX) is the stronger pick with 12.

9% revenue growth year-over-year, versus 2. 4% for Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. (GILD) offers the better valuation at 19. 8x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Gilead Sciences, Inc.

(GILD) is the cheapest at 19. 8x versus AbbVie Inc. at 85. 5x. On forward P/E, Xerox Holdings Corporation is actually cheaper at 5. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to -74. 1% for Xerox Holdings Corporation (XRX). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus XRX's -42. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Xerox Holdings Corporation's 2. 68β — meaning XRX is approximately 694% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Eastman Kodak Company (KODK) carries a lower debt/equity ratio of 35% versus 6% for Xerox Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xerox Holdings Corporation (XRX) is pulling ahead at 12.

9% versus 2. 4% for Gilead Sciences, Inc. (GILD). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -297. 8% for Eastman Kodak Company. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus -14. 7% for Xerox Holdings Corporation — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus -0. 8% for XRX. At the gross margin level — before operating expenses — GILD leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Xerox Holdings Corporation (XRX) trades at 5.

1x forward P/E versus 15. 7x for Gilead Sciences, Inc. — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XRX: 332. 5% to $10. 25.

All stocks in this comparison pay dividends.

Xerox Holdings Corporation (XRX) offers the highest yield at 23. 7%, versus 0. 2% for Eastman Kodak Company (KODK).

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Eastman Kodak Company (KODK) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, KODK: +20. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (KODK (Industrials) and AMGN (Healthcare) and GILD (Healthcare) and XRX (Technology) and ABBV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KODK is a small-cap quality compounder stock; AMGN is a mid-cap quality compounder stock; GILD is a mid-cap quality compounder stock; XRX is a small-cap income-oriented stock; ABBV is a large-cap income-oriented stock. AMGN, GILD, XRX, ABBV pay a dividend while KODK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.